Literature DB >> 24615359

Experimental selection of paromomycin and miltefosine resistance in intracellular amastigotes of Leishmania donovani and L. infantum.

S Hendrickx1, G Boulet, A Mondelaers, J C Dujardin, S Rijal, L Lachaud, P Cos, P Delputte, L Maes.   

Abstract

Although widespread resistance of Leishmania donovani and L. infantum against miltefosine (MIL) and paromomycin (PMM) has not yet been demonstrated, both run the risk of resistance selection. Unraveling the dynamics and mechanisms of resistance development is key to preserve drug efficacy in the field. In this study, resistance against PMM and MIL was experimentally selected in vitro in intracellular amastigotes of several strains of both species with different antimony susceptibility background. To monitor amastigote susceptibility, microscopic determination of IC50-values and promastigote back-transformation assays were performed. Both techniques were also used to evaluate the susceptibility of field isolates from MIL-relapse patients. PMM-resistance could readily be selected in all species/strains, although promastigotes remained fully PMM-susceptible. Successful MIL-resistance selection was demonstrated only by promastigote back-transformation at increasing MIL-concentrations upon successive selection cycles. Important to note is that amastigotes with the MIL-resistant phenotype could not be visualized after Giemsa staining; hence, MIL-IC50-values showed no shift. The same phenomenon was observed in a set of recent clinical isolates from MIL-relapse patients. This study clearly endorses the need to use intracellular amastigotes for PMM- and MIL-susceptibility testing. When monitoring MIL-resistance, promastigote back-transformation should be used instead of the standard Giemsa staining. In-depth exploration of the mechanistic background of this finding is warranted.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24615359     DOI: 10.1007/s00436-014-3835-7

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  26 in total

1.  Kala-azar elimination programme in India.

Authors:  G P S Dhillon; S N Sharma; Bindu Nair
Journal:  J Indian Med Assoc       Date:  2008-10

2.  Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani.

Authors:  Arpita Kulshrestha; Vasundhra Bhandari; Rupkatha Mukhopadhyay; V Ramesh; Shyam Sundar; Louis Maes; Jean Claude Dujardin; Syamal Roy; Poonam Salotra
Journal:  Parasitol Res       Date:  2012-12-13       Impact factor: 2.289

3.  Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance.

Authors:  Tim Downing; Hideo Imamura; Saskia Decuypere; Taane G Clark; Graham H Coombs; James A Cotton; James D Hilley; Simonne de Doncker; Ilse Maes; Jeremy C Mottram; Mike A Quail; Suman Rijal; Mandy Sanders; Gabriele Schönian; Olivia Stark; Shyam Sundar; Manu Vanaerschot; Christiane Hertz-Fowler; Jean-Claude Dujardin; Matthew Berriman
Journal:  Genome Res       Date:  2011-10-28       Impact factor: 9.043

Review 4.  Combination therapy for visceral leishmaniasis.

Authors:  Johan van Griensven; Manica Balasegaram; Filip Meheus; Jorge Alvar; Lutgarde Lynen; Marleen Boelaert
Journal:  Lancet Infect Dis       Date:  2010-03       Impact factor: 25.071

5.  In vitro and in vivo prophylactic and curative activity of the triterpene saponin PX-6518 against cutaneous Leishmania species.

Authors:  Raquel Andreia Inocêncio da Luz; Marieke Vermeersch; Maartje Deschacht; Sarah Hendrickx; Tim Van Assche; Paul Cos; Louis Maes
Journal:  J Antimicrob Chemother       Date:  2010-12-03       Impact factor: 5.790

6.  Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance.

Authors:  Suman Rijal; Bart Ostyn; Surendra Uranw; Keshav Rai; Narayan Raj Bhattarai; Thomas P C Dorlo; Jos H Beijnen; Manu Vanaerschot; Saskia Decuypere; Subodh S Dhakal; Murari Lal Das; Prahlad Karki; Rupa Singh; Marleen Boelaert; Jean-Claude Dujardin
Journal:  Clin Infect Dis       Date:  2013-02-20       Impact factor: 9.079

Review 7.  Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis.

Authors:  Thomas P C Dorlo; Manica Balasegaram; Jos H Beijnen; Peter J de Vries
Journal:  J Antimicrob Chemother       Date:  2012-07-24       Impact factor: 5.790

8.  In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences.

Authors:  Marieke Vermeersch; Raquel Inocêncio da Luz; Kim Toté; Jean-Pierre Timmermans; Paul Cos; Louis Maes
Journal:  Antimicrob Agents Chemother       Date:  2009-06-22       Impact factor: 5.191

9.  Leishmania resistance to miltefosine associated with genetic marker.

Authors:  Sandrine Cojean; Sandrine Houzé; Djamel Haouchine; Françoise Huteau; Sylvie Lariven; Véronique Hubert; Florence Michard; Christian Bories; Francine Pratlong; Jacques Le Bras; Philippe Marie Loiseau; Sophie Matheron
Journal:  Emerg Infect Dis       Date:  2012-04       Impact factor: 6.883

10.  Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management.

Authors:  Shyam Sundar; Piero L Olliaro
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423

View more
  29 in total

1.  Intracellular amastigote replication may not be required for successful in vitro selection of miltefosine resistance in Leishmania infantum.

Authors:  S Hendrickx; A Mondelaers; E Eberhardt; L Lachaud; P Delputte; P Cos; L Maes
Journal:  Parasitol Res       Date:  2015-04-17       Impact factor: 2.289

2.  Zinc(II)-Dipicolylamine Coordination Complexes as Targeting and Chemotherapeutic Agents for Leishmania major.

Authors:  Douglas R Rice; Paola Vacchina; Brianna Norris-Mullins; Miguel A Morales; Bradley D Smith
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

3.  Molecular detection of infection homogeneity and impact of miltefosine treatment in a Syrian golden hamster model of Leishmania donovani and L. infantum visceral leishmaniasis.

Authors:  Eline Eberhardt; Annelies Mondelaers; Sarah Hendrickx; Magali Van den Kerkhof; Louis Maes; Guy Caljon
Journal:  Parasitol Res       Date:  2016-07-13       Impact factor: 2.289

Review 4.  Artemisinin and its derivatives in treating protozoan infections beyond malaria.

Authors:  Cecilia Shi Ni Loo; Nelson Siu Kei Lam; Deying Yu; Xin-Zhuan Su; Fangli Lu
Journal:  Pharmacol Res       Date:  2016-11-17       Impact factor: 7.658

5.  In Vivo Selection of Paromomycin and Miltefosine Resistance in Leishmania donovani and L. infantum in a Syrian Hamster Model.

Authors:  S Hendrickx; A Mondelaers; E Eberhardt; P Delputte; P Cos; L Maes
Journal:  Antimicrob Agents Chemother       Date:  2015-05-26       Impact factor: 5.191

6.  Deep-sequencing revealing mutation dynamics in the miltefosine transporter gene in Leishmania infantum selected for miltefosine resistance.

Authors:  Marie-Claude N Laffitte; Philippe Leprohon; Danielle Légaré; Marc Ouellette
Journal:  Parasitol Res       Date:  2016-07-26       Impact factor: 2.289

7.  Genomic Appraisal of the Multifactorial Basis for In Vitro Acquisition of Miltefosine Resistance in Leishmania donovani.

Authors:  P Vacchina; B Norris-Mullins; M A Abengózar; C G Viamontes; J Sarro; M T Stephens; M E Pfrender; L Rivas; M A Morales
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

8.  Comparative Fitness of a Parent Leishmania donovani Clinical Isolate and Its Experimentally Derived Paromomycin-Resistant Strain.

Authors:  Sarah Hendrickx; Annelies Leemans; Annelies Mondelaers; Suman Rijal; Basudha Khanal; Jean-Claude Dujardin; Peter Delputte; Paul Cos; Louis Maes
Journal:  PLoS One       Date:  2015-10-15       Impact factor: 3.240

9.  Fitness and Phenotypic Characterization of Miltefosine-Resistant Leishmania major.

Authors:  Kimbra G Turner; Paola Vacchina; Maricela Robles-Murguia; Mariha Wadsworth; Mary Ann McDowell; Miguel A Morales
Journal:  PLoS Negl Trop Dis       Date:  2015-07-31

10.  Leishmania is not prone to develop resistance to tamoxifen.

Authors:  Adriano C Coelho; Cristiana T Trinconi; Luisa Senra; Jenicer K U Yokoyama-Yasunaka; Silvia R B Uliana
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2015-06-17       Impact factor: 4.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.